Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV

February 18, 2011 By Bio-Medicine.Org

CORK, Ireland, Feb. 18, 2011 /PRNewswire/ — Tibotec
Pharmaceuticals announced today that two global, registrational
phase 3 trials are recruiting patients to examine TMC435, its
investigational hepatitis C protease inhibitor, in treatment-naive
adults with chronic genotype 1 hepatitis C virus (HCV). A third
global phase 3 trial is being conducted in genotype 1 HCV patients
who have experienced a viral relapse after prior interferon-based
treatment. Approximately 3.2 million people in the U.S. live with
chronic hepatitis C disease and more than 170 million people have
the disease globally. The response-guided trials will compare the
efficacy, safety and tolerability of TMC435 given as a single 150
mg oral tablet once daily for 12 weeks versus placebo; each patient
also will be treated with a background regimen of peginterferon and
ribavirin for 24 or 48 weeks.

“TMC435 is an important component of our growing HCV pipeline,”
said Brian Woodfall M.D., Vice President of Global Clinical
Development at Tibotec. “The initiation of the TMC435 phase 3
clinical trial program reinforces our commitment to develop
innovative new treatment options that may decrease the duration of
treatment for patients with chronic hepatitis C infection.”

The first global, phase 3, double-blind, randomized study, known
as TMC435-C208 or QUEST-1 (QD dosing of TMC435 of
previoUsly untreated GEnotype 1 patienTs-1),
will evaluate a single TMC435 once-daily oral tablet (150 mg)
versus placebo in treatment-naive HCV patients. Both groups will
also receive peginterferon alfa-2a (Pegasys®) and ribavirin
(Copegus®) as part of their treatment. The second global, phase
3, double-blind, randomized study, known as TMC435-C216 or QUEST-2
(QD dosing of TMC435 of previoUsly untreated
GEnotype 1 patienTs-2), also will evaluate a single
TMC435 once-daily oral tablet (150 mg) versus placebo in
treatment-naive HCV patients. However,

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech